Review



aav dio hm3dq  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Addgene inc aav dio hm3dq
    ( A ) Experimental timeline. AAV vectors were injected into the nodose ganglion (NG) 28 days before the forced mouth-opening (FMO) procedure. FMO was performed for 3 h per day across five consecutive days. Facial mechanical thresholds (von Frey), grimace scores (MGS), and open-field activity were assessed at baseline and multiple time points after FMO. C21 was administered intraperitoneally once daily for 2 days beginning on day 1 post-FMO, and conditioned place-preference (CPP) testing was conducted between days 9–13 post-FMO. ( B ) Representative confocal fluorescence images of NG showing mCherry reporter expression following viral infection, with nuclei counterstained with DAPI. ( C ) Facial withdrawal thresholds across different Cre lines and wild-type after FMO. C21 was administered intraperitoneally after von Frey testing once daily on day 1 and 2 after FMO. Cre-driver mice received nodose ganglion <t>injection</t> <t>of</t> <t>AAV-DIO-hM3Dq</t> and control mice received AAV-DIO-mCherry, both received intraperitoneal C21 after injection. ( D ) Facial withdrawal thresholds in DAT-Cre mice or wild type mice with or without intra-TMJ injection of C21. DAT-cre mice received nodose ganglion injection of AAV-DIO-hM3Dq, followed by intra-TMJ injection of C21 or vehicle. Data are presented as mean ± s.e.m.: *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test). ( E ) Representative facial images of WT and DAT-Cre mice before and after FMO with or without C21 treatment. ( F ) Quantification of spontaneous pain using the Mouse Grimace Scale (MGS). DAT-Cre + C21 mice exhibited significantly reduced MGS scores on day 5 and day 7 post-FMO compared to control groups. Data are mean ± s.e.m.; **p < 0.01, ***p < 0.001, ###p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test).
    Aav Dio Hm3dq, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 666 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/aav dio hm3dq/product/Addgene inc
    Average 96 stars, based on 666 article reviews
    aav dio hm3dq - by Bioz Stars, 2026-06
    96/100 stars

    Images

    1) Product Images from "Vagal dopaminergic afferents link interoception to trigeminal pain modulation"

    Article Title: Vagal dopaminergic afferents link interoception to trigeminal pain modulation

    Journal: bioRxiv

    doi: 10.64898/2026.03.27.714928

    ( A ) Experimental timeline. AAV vectors were injected into the nodose ganglion (NG) 28 days before the forced mouth-opening (FMO) procedure. FMO was performed for 3 h per day across five consecutive days. Facial mechanical thresholds (von Frey), grimace scores (MGS), and open-field activity were assessed at baseline and multiple time points after FMO. C21 was administered intraperitoneally once daily for 2 days beginning on day 1 post-FMO, and conditioned place-preference (CPP) testing was conducted between days 9–13 post-FMO. ( B ) Representative confocal fluorescence images of NG showing mCherry reporter expression following viral infection, with nuclei counterstained with DAPI. ( C ) Facial withdrawal thresholds across different Cre lines and wild-type after FMO. C21 was administered intraperitoneally after von Frey testing once daily on day 1 and 2 after FMO. Cre-driver mice received nodose ganglion injection of AAV-DIO-hM3Dq and control mice received AAV-DIO-mCherry, both received intraperitoneal C21 after injection. ( D ) Facial withdrawal thresholds in DAT-Cre mice or wild type mice with or without intra-TMJ injection of C21. DAT-cre mice received nodose ganglion injection of AAV-DIO-hM3Dq, followed by intra-TMJ injection of C21 or vehicle. Data are presented as mean ± s.e.m.: *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test). ( E ) Representative facial images of WT and DAT-Cre mice before and after FMO with or without C21 treatment. ( F ) Quantification of spontaneous pain using the Mouse Grimace Scale (MGS). DAT-Cre + C21 mice exhibited significantly reduced MGS scores on day 5 and day 7 post-FMO compared to control groups. Data are mean ± s.e.m.; **p < 0.01, ***p < 0.001, ###p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test).
    Figure Legend Snippet: ( A ) Experimental timeline. AAV vectors were injected into the nodose ganglion (NG) 28 days before the forced mouth-opening (FMO) procedure. FMO was performed for 3 h per day across five consecutive days. Facial mechanical thresholds (von Frey), grimace scores (MGS), and open-field activity were assessed at baseline and multiple time points after FMO. C21 was administered intraperitoneally once daily for 2 days beginning on day 1 post-FMO, and conditioned place-preference (CPP) testing was conducted between days 9–13 post-FMO. ( B ) Representative confocal fluorescence images of NG showing mCherry reporter expression following viral infection, with nuclei counterstained with DAPI. ( C ) Facial withdrawal thresholds across different Cre lines and wild-type after FMO. C21 was administered intraperitoneally after von Frey testing once daily on day 1 and 2 after FMO. Cre-driver mice received nodose ganglion injection of AAV-DIO-hM3Dq and control mice received AAV-DIO-mCherry, both received intraperitoneal C21 after injection. ( D ) Facial withdrawal thresholds in DAT-Cre mice or wild type mice with or without intra-TMJ injection of C21. DAT-cre mice received nodose ganglion injection of AAV-DIO-hM3Dq, followed by intra-TMJ injection of C21 or vehicle. Data are presented as mean ± s.e.m.: *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test). ( E ) Representative facial images of WT and DAT-Cre mice before and after FMO with or without C21 treatment. ( F ) Quantification of spontaneous pain using the Mouse Grimace Scale (MGS). DAT-Cre + C21 mice exhibited significantly reduced MGS scores on day 5 and day 7 post-FMO compared to control groups. Data are mean ± s.e.m.; **p < 0.01, ***p < 0.001, ###p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test).

    Techniques Used: Injection, Activity Assay, Conditioned Place Preference, Fluorescence, Expressing, Infection, Control



    Similar Products

    86
    Jackson Laboratory lsl hm3dq
    Lsl Hm3dq, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lsl hm3dq/product/Jackson Laboratory
    Average 86 stars, based on 1 article reviews
    lsl hm3dq - by Bioz Stars, 2026-06
    86/100 stars
      Buy from Supplier

    86
    Jackson Laboratory rosa26 lsl hm3dq
    Rosa26 Lsl Hm3dq, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rosa26 lsl hm3dq/product/Jackson Laboratory
    Average 86 stars, based on 1 article reviews
    rosa26 lsl hm3dq - by Bioz Stars, 2026-06
    86/100 stars
      Buy from Supplier

    86
    Novo Nordisk iowa viral vector core n a aav hsyn dio hm3dq gq mcherry addgene
    Iowa Viral Vector Core N A Aav Hsyn Dio Hm3dq Gq Mcherry Addgene, supplied by Novo Nordisk, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/iowa viral vector core n a aav hsyn dio hm3dq gq mcherry addgene/product/Novo Nordisk
    Average 86 stars, based on 1 article reviews
    iowa viral vector core n a aav hsyn dio hm3dq gq mcherry addgene - by Bioz Stars, 2026-06
    86/100 stars
      Buy from Supplier

    96
    Addgene inc aav dio hm3dq
    ( A ) Experimental timeline. AAV vectors were injected into the nodose ganglion (NG) 28 days before the forced mouth-opening (FMO) procedure. FMO was performed for 3 h per day across five consecutive days. Facial mechanical thresholds (von Frey), grimace scores (MGS), and open-field activity were assessed at baseline and multiple time points after FMO. C21 was administered intraperitoneally once daily for 2 days beginning on day 1 post-FMO, and conditioned place-preference (CPP) testing was conducted between days 9–13 post-FMO. ( B ) Representative confocal fluorescence images of NG showing mCherry reporter expression following viral infection, with nuclei counterstained with DAPI. ( C ) Facial withdrawal thresholds across different Cre lines and wild-type after FMO. C21 was administered intraperitoneally after von Frey testing once daily on day 1 and 2 after FMO. Cre-driver mice received nodose ganglion <t>injection</t> <t>of</t> <t>AAV-DIO-hM3Dq</t> and control mice received AAV-DIO-mCherry, both received intraperitoneal C21 after injection. ( D ) Facial withdrawal thresholds in DAT-Cre mice or wild type mice with or without intra-TMJ injection of C21. DAT-cre mice received nodose ganglion injection of AAV-DIO-hM3Dq, followed by intra-TMJ injection of C21 or vehicle. Data are presented as mean ± s.e.m.: *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test). ( E ) Representative facial images of WT and DAT-Cre mice before and after FMO with or without C21 treatment. ( F ) Quantification of spontaneous pain using the Mouse Grimace Scale (MGS). DAT-Cre + C21 mice exhibited significantly reduced MGS scores on day 5 and day 7 post-FMO compared to control groups. Data are mean ± s.e.m.; **p < 0.01, ***p < 0.001, ###p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test).
    Aav Dio Hm3dq, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/aav dio hm3dq/product/Addgene inc
    Average 96 stars, based on 1 article reviews
    aav dio hm3dq - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    86
    Obio Technology Corp Ltd virus aav ef1α dio hm3dq mcherry
    ( A ) Experimental timeline. AAV vectors were injected into the nodose ganglion (NG) 28 days before the forced mouth-opening (FMO) procedure. FMO was performed for 3 h per day across five consecutive days. Facial mechanical thresholds (von Frey), grimace scores (MGS), and open-field activity were assessed at baseline and multiple time points after FMO. C21 was administered intraperitoneally once daily for 2 days beginning on day 1 post-FMO, and conditioned place-preference (CPP) testing was conducted between days 9–13 post-FMO. ( B ) Representative confocal fluorescence images of NG showing mCherry reporter expression following viral infection, with nuclei counterstained with DAPI. ( C ) Facial withdrawal thresholds across different Cre lines and wild-type after FMO. C21 was administered intraperitoneally after von Frey testing once daily on day 1 and 2 after FMO. Cre-driver mice received nodose ganglion <t>injection</t> <t>of</t> <t>AAV-DIO-hM3Dq</t> and control mice received AAV-DIO-mCherry, both received intraperitoneal C21 after injection. ( D ) Facial withdrawal thresholds in DAT-Cre mice or wild type mice with or without intra-TMJ injection of C21. DAT-cre mice received nodose ganglion injection of AAV-DIO-hM3Dq, followed by intra-TMJ injection of C21 or vehicle. Data are presented as mean ± s.e.m.: *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test). ( E ) Representative facial images of WT and DAT-Cre mice before and after FMO with or without C21 treatment. ( F ) Quantification of spontaneous pain using the Mouse Grimace Scale (MGS). DAT-Cre + C21 mice exhibited significantly reduced MGS scores on day 5 and day 7 post-FMO compared to control groups. Data are mean ± s.e.m.; **p < 0.01, ***p < 0.001, ###p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test).
    Virus Aav Ef1α Dio Hm3dq Mcherry, supplied by Obio Technology Corp Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/virus aav ef1α dio hm3dq mcherry/product/Obio Technology Corp Ltd
    Average 86 stars, based on 1 article reviews
    virus aav ef1α dio hm3dq mcherry - by Bioz Stars, 2026-06
    86/100 stars
      Buy from Supplier

    94
    Addgene inc dr william wisden
    ( A ) Experimental timeline. AAV vectors were injected into the nodose ganglion (NG) 28 days before the forced mouth-opening (FMO) procedure. FMO was performed for 3 h per day across five consecutive days. Facial mechanical thresholds (von Frey), grimace scores (MGS), and open-field activity were assessed at baseline and multiple time points after FMO. C21 was administered intraperitoneally once daily for 2 days beginning on day 1 post-FMO, and conditioned place-preference (CPP) testing was conducted between days 9–13 post-FMO. ( B ) Representative confocal fluorescence images of NG showing mCherry reporter expression following viral infection, with nuclei counterstained with DAPI. ( C ) Facial withdrawal thresholds across different Cre lines and wild-type after FMO. C21 was administered intraperitoneally after von Frey testing once daily on day 1 and 2 after FMO. Cre-driver mice received nodose ganglion <t>injection</t> <t>of</t> <t>AAV-DIO-hM3Dq</t> and control mice received AAV-DIO-mCherry, both received intraperitoneal C21 after injection. ( D ) Facial withdrawal thresholds in DAT-Cre mice or wild type mice with or without intra-TMJ injection of C21. DAT-cre mice received nodose ganglion injection of AAV-DIO-hM3Dq, followed by intra-TMJ injection of C21 or vehicle. Data are presented as mean ± s.e.m.: *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test). ( E ) Representative facial images of WT and DAT-Cre mice before and after FMO with or without C21 treatment. ( F ) Quantification of spontaneous pain using the Mouse Grimace Scale (MGS). DAT-Cre + C21 mice exhibited significantly reduced MGS scores on day 5 and day 7 post-FMO compared to control groups. Data are mean ± s.e.m.; **p < 0.01, ***p < 0.001, ###p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test).
    Dr William Wisden, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dr william wisden/product/Addgene inc
    Average 94 stars, based on 1 article reviews
    dr william wisden - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    94
    Addgene inc hm3dq mcherry
    A: Experimental design for cortex-restricted chemogenetic activation. An expression plasmid <t>for</t> <t>hM3Dq-mCherry</t> was in utero electroporated unilaterally to the dorsolateral cortex of ICR wild-type embryos at E12.5-15.5. After the resulting male mice grew up till postnatal 8 week, CNO or vehicle PBS was intraperitoneally administered to the mice, and the pupil sizes of both eyes were measured in a dark room. B: Boxplot showing the pupil diameters from eyes at 20-50 mins after administration of PBS (pale yellow) and CNO (blue) in ICR mice whose cortices were in utero electroporated for hM3Dq at E12.5, E13.5, E14.5 and E15.5. The black line shows the difference of pupil diameters in individual eyes between PBS and CNO treatments. X marks the mean. One-tailed paired t-tests were performed between PBS and CNO treatments. C, D: Distribution of hM3Dq-positive areas and FOS-positive neurons in cortical layers of somatosensory areas on the in utero electroporated (EP) and unelectroporated (non-EP) sides. The same mice in B were analyzed at postmortem.
    Hm3dq Mcherry, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hm3dq mcherry/product/Addgene inc
    Average 94 stars, based on 1 article reviews
    hm3dq mcherry - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    86
    Janvier Labs hm3dq experiment
    A: Experimental design for cortex-restricted chemogenetic activation. An expression plasmid <t>for</t> <t>hM3Dq-mCherry</t> was in utero electroporated unilaterally to the dorsolateral cortex of ICR wild-type embryos at E12.5-15.5. After the resulting male mice grew up till postnatal 8 week, CNO or vehicle PBS was intraperitoneally administered to the mice, and the pupil sizes of both eyes were measured in a dark room. B: Boxplot showing the pupil diameters from eyes at 20-50 mins after administration of PBS (pale yellow) and CNO (blue) in ICR mice whose cortices were in utero electroporated for hM3Dq at E12.5, E13.5, E14.5 and E15.5. The black line shows the difference of pupil diameters in individual eyes between PBS and CNO treatments. X marks the mean. One-tailed paired t-tests were performed between PBS and CNO treatments. C, D: Distribution of hM3Dq-positive areas and FOS-positive neurons in cortical layers of somatosensory areas on the in utero electroporated (EP) and unelectroporated (non-EP) sides. The same mice in B were analyzed at postmortem.
    Hm3dq Experiment, supplied by Janvier Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hm3dq experiment/product/Janvier Labs
    Average 86 stars, based on 1 article reviews
    hm3dq experiment - by Bioz Stars, 2026-06
    86/100 stars
      Buy from Supplier

    93
    Addgene inc hm3dq
    A: Experimental design for cortex-restricted chemogenetic activation. An expression plasmid <t>for</t> <t>hM3Dq-mCherry</t> was in utero electroporated unilaterally to the dorsolateral cortex of ICR wild-type embryos at E12.5-15.5. After the resulting male mice grew up till postnatal 8 week, CNO or vehicle PBS was intraperitoneally administered to the mice, and the pupil sizes of both eyes were measured in a dark room. B: Boxplot showing the pupil diameters from eyes at 20-50 mins after administration of PBS (pale yellow) and CNO (blue) in ICR mice whose cortices were in utero electroporated for hM3Dq at E12.5, E13.5, E14.5 and E15.5. The black line shows the difference of pupil diameters in individual eyes between PBS and CNO treatments. X marks the mean. One-tailed paired t-tests were performed between PBS and CNO treatments. C, D: Distribution of hM3Dq-positive areas and FOS-positive neurons in cortical layers of somatosensory areas on the in utero electroporated (EP) and unelectroporated (non-EP) sides. The same mice in B were analyzed at postmortem.
    Hm3dq, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hm3dq/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    hm3dq - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) Experimental timeline. AAV vectors were injected into the nodose ganglion (NG) 28 days before the forced mouth-opening (FMO) procedure. FMO was performed for 3 h per day across five consecutive days. Facial mechanical thresholds (von Frey), grimace scores (MGS), and open-field activity were assessed at baseline and multiple time points after FMO. C21 was administered intraperitoneally once daily for 2 days beginning on day 1 post-FMO, and conditioned place-preference (CPP) testing was conducted between days 9–13 post-FMO. ( B ) Representative confocal fluorescence images of NG showing mCherry reporter expression following viral infection, with nuclei counterstained with DAPI. ( C ) Facial withdrawal thresholds across different Cre lines and wild-type after FMO. C21 was administered intraperitoneally after von Frey testing once daily on day 1 and 2 after FMO. Cre-driver mice received nodose ganglion injection of AAV-DIO-hM3Dq and control mice received AAV-DIO-mCherry, both received intraperitoneal C21 after injection. ( D ) Facial withdrawal thresholds in DAT-Cre mice or wild type mice with or without intra-TMJ injection of C21. DAT-cre mice received nodose ganglion injection of AAV-DIO-hM3Dq, followed by intra-TMJ injection of C21 or vehicle. Data are presented as mean ± s.e.m.: *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test). ( E ) Representative facial images of WT and DAT-Cre mice before and after FMO with or without C21 treatment. ( F ) Quantification of spontaneous pain using the Mouse Grimace Scale (MGS). DAT-Cre + C21 mice exhibited significantly reduced MGS scores on day 5 and day 7 post-FMO compared to control groups. Data are mean ± s.e.m.; **p < 0.01, ***p < 0.001, ###p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test).

    Journal: bioRxiv

    Article Title: Vagal dopaminergic afferents link interoception to trigeminal pain modulation

    doi: 10.64898/2026.03.27.714928

    Figure Lengend Snippet: ( A ) Experimental timeline. AAV vectors were injected into the nodose ganglion (NG) 28 days before the forced mouth-opening (FMO) procedure. FMO was performed for 3 h per day across five consecutive days. Facial mechanical thresholds (von Frey), grimace scores (MGS), and open-field activity were assessed at baseline and multiple time points after FMO. C21 was administered intraperitoneally once daily for 2 days beginning on day 1 post-FMO, and conditioned place-preference (CPP) testing was conducted between days 9–13 post-FMO. ( B ) Representative confocal fluorescence images of NG showing mCherry reporter expression following viral infection, with nuclei counterstained with DAPI. ( C ) Facial withdrawal thresholds across different Cre lines and wild-type after FMO. C21 was administered intraperitoneally after von Frey testing once daily on day 1 and 2 after FMO. Cre-driver mice received nodose ganglion injection of AAV-DIO-hM3Dq and control mice received AAV-DIO-mCherry, both received intraperitoneal C21 after injection. ( D ) Facial withdrawal thresholds in DAT-Cre mice or wild type mice with or without intra-TMJ injection of C21. DAT-cre mice received nodose ganglion injection of AAV-DIO-hM3Dq, followed by intra-TMJ injection of C21 or vehicle. Data are presented as mean ± s.e.m.: *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test). ( E ) Representative facial images of WT and DAT-Cre mice before and after FMO with or without C21 treatment. ( F ) Quantification of spontaneous pain using the Mouse Grimace Scale (MGS). DAT-Cre + C21 mice exhibited significantly reduced MGS scores on day 5 and day 7 post-FMO compared to control groups. Data are mean ± s.e.m.; **p < 0.01, ***p < 0.001, ###p < 0.001 (two-way ANOVA followed by Tukey’s multiple-comparisons test).

    Article Snippet: For selective activation of dopaminergic vagal neurons, AAV-DIO-hM3Dq (#44361; Addgene) or AAV-DIO-mCherry (control) (#50459; Addgene) was injected unilaterally into the right nodose ganglion of Cre-driver mice.

    Techniques: Injection, Activity Assay, Conditioned Place Preference, Fluorescence, Expressing, Infection, Control

    A: Experimental design for cortex-restricted chemogenetic activation. An expression plasmid for hM3Dq-mCherry was in utero electroporated unilaterally to the dorsolateral cortex of ICR wild-type embryos at E12.5-15.5. After the resulting male mice grew up till postnatal 8 week, CNO or vehicle PBS was intraperitoneally administered to the mice, and the pupil sizes of both eyes were measured in a dark room. B: Boxplot showing the pupil diameters from eyes at 20-50 mins after administration of PBS (pale yellow) and CNO (blue) in ICR mice whose cortices were in utero electroporated for hM3Dq at E12.5, E13.5, E14.5 and E15.5. The black line shows the difference of pupil diameters in individual eyes between PBS and CNO treatments. X marks the mean. One-tailed paired t-tests were performed between PBS and CNO treatments. C, D: Distribution of hM3Dq-positive areas and FOS-positive neurons in cortical layers of somatosensory areas on the in utero electroporated (EP) and unelectroporated (non-EP) sides. The same mice in B were analyzed at postmortem.

    Journal: bioRxiv

    Article Title: Phenotype-driven screening reveals a causal role for the cortex in pupil control

    doi: 10.64898/2026.03.17.712501

    Figure Lengend Snippet: A: Experimental design for cortex-restricted chemogenetic activation. An expression plasmid for hM3Dq-mCherry was in utero electroporated unilaterally to the dorsolateral cortex of ICR wild-type embryos at E12.5-15.5. After the resulting male mice grew up till postnatal 8 week, CNO or vehicle PBS was intraperitoneally administered to the mice, and the pupil sizes of both eyes were measured in a dark room. B: Boxplot showing the pupil diameters from eyes at 20-50 mins after administration of PBS (pale yellow) and CNO (blue) in ICR mice whose cortices were in utero electroporated for hM3Dq at E12.5, E13.5, E14.5 and E15.5. The black line shows the difference of pupil diameters in individual eyes between PBS and CNO treatments. X marks the mean. One-tailed paired t-tests were performed between PBS and CNO treatments. C, D: Distribution of hM3Dq-positive areas and FOS-positive neurons in cortical layers of somatosensory areas on the in utero electroporated (EP) and unelectroporated (non-EP) sides. The same mice in B were analyzed at postmortem.

    Article Snippet: pAAV-PTRE-tight -hM3Dq-mCherry was obtained from Dr William Wisden (Addgene plasmid # 66795) and the coding sequences for hM3Dq fused with mCherry were subcloned into a CAGGS expression plasmid .

    Techniques: Activation Assay, Expressing, Plasmid Preparation, In Utero, One-tailed Test